Alpha-1 Protease Inhibitor Deficiency Market

Abstract
DelveInsight’s ‘Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Alpha-1 Protease Inhibitor Deficiency in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Alpha-1 Protease Inhibitor Deficiency market report provides analysis regarding current treatment practices, emerging drugs like Gaboxadol, potential therapies, market share of the individual therapies, historical, current and forecasted Alpha-1 Protease Inhibitor Deficiency market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Alpha-1 Protease Inhibitor Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Alpha-1 Protease Inhibitor Deficiency- Disease Understanding and Treatment Algorithm

Alpha-1 Protease Inhibitor Deficiency Overview

Alpha-1 Protease Inhibitor Deficiency (AS) is a complex genetic disorder that primarily affects the nervous system. The characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia). Most affected children also have recurrent seizures (epilepsy) and small head size (microcephaly).

It is caused by a variety of genetic abnormalities involving the chromosome 15q11-13 region, which is subjected to genomic imprinting. These include maternal deletion, paternal uniparental disomy, imprinting defects, point mutations or small deletions within the UBE3A gene, which lies within this region. Delayed development becomes noticeable by the age of 6–12 months, and other common signs and symptoms usually appear in early childhood. Children with Alpha-1 Protease Inhibitor Deficiency experience delays in reaching developmental milestones (developmental delays) and have severe learning disabilities. Besides, Alpha-1 Protease Inhibitor Deficiency affects males and females in equal numbers.

Alpha-1 Protease Inhibitor Deficiency Treatment

This chapter covers the details of conventional and current medical therapies available in the Alpha-1 Protease Inhibitor Deficiency market for the treatment of the condition. It also provides the country-wise Alpha-1 Protease Inhibitor Deficiency treatment guidelines across the United States, Europe and Japan.

DelveInsight’s Alpha-1 Protease Inhibitor Deficiency market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Alpha-1 Protease Inhibitor Deficiency treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Alpha-1 Protease Inhibitor Deficiency Epidemiology

The Alpha-1 Protease Inhibitor Deficiency epidemiology chapters provide insights about historical and current Alpha-1 Protease Inhibitor Deficiency patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Alpha-1 Protease Inhibitor Deficiency epidemiology is segmented by Prevalent and Diagnosed
cases of Alpha-1 Protease Inhibitor Deficiency, Cases of Alpha-1 Protease Inhibitor Deficiency by Mutation Types and Alpha-1 Protease Inhibitor Deficiency cases by Clinical Manifestations. The report includes a thorough analysis of all segmentations.

In the US, the cases of Alpha-1 Protease Inhibitor Deficiency were found to be 21,715 in 2017. Moreover, the diagnosed cases of Alpha-1 Protease Inhibitor Deficiency were reported to be 19,543 in the United States. The United States accounts for the highest diagnosed cases of Alpha-1 Protease Inhibitor Deficiency.

According to DelveInsight’s, the total prevalent population of Alpha-1 Protease Inhibitor Deficiency in seven major markets was 57,716 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).

Among all the seven major markets, the United States accounts for the highest Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency cases.

Alpha-1 Protease Inhibitor Deficiency Drug Chapters

Drug chapter segment of the Alpha-1 Protease Inhibitor Deficiency report encloses the detailed analysis of Alpha-1 Protease Inhibitor Deficiency pipeline drug. It also helps to understand the Alpha-1 Protease Inhibitor Deficiency clinical trial details, expressive pharmacological action, agreements of included drug and the latest news and press releases.

Treatment is focused entirely on the management of symptoms and supporting the health and well-being of the affected child or adult. The management of Alpha-1 Protease Inhibitor Deficiency revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. Ovid Therapeutics’ Gaboxadol is one of the therapies in the pipeline.

Alpha-1 Protease Inhibitor Deficiency Market Outlook
The Alpha-1 Protease Inhibitor Deficiency market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Alpha-1 Protease Inhibitor Deficiency market size with USD 110 million in 2017, while Spain had the smallest market size of Alpha-1 Protease Inhibitor Deficiency with USD 16 million in 2017.
Alpha-1 Protease Inhibitor Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Alpha-1 Protease Inhibitor Deficiency market or expected to get launched in the market during the study period 2017–2030. The analysis covers Alpha-1 Protease Inhibitor Deficiency market uptake by drugs; patient uptake by therapies; and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Alpha-1 Protease Inhibitor Deficiency market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Alpha-1 Protease Inhibitor Deficiency Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Alpha-1 Protease Inhibitor Deficiency key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Alpha-1 Protease Inhibitor Deficiency collaborations, acquisition and merger, licensing, patent details and other information for Alpha-1 Protease Inhibitor Deficiency emerging therapies.

Reimbursement Scenario in Alpha-1 Protease Inhibitor Deficiency

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Alpha-1 Protease Inhibitor Deficiency domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alpha-1 Protease Inhibitor Deficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights
• In the coming years, Alpha-1 Protease Inhibitor Deficiency market scenario is expected to alter across the 7 MM due to launch of novel therapies with new mechanisms of action considering the high unmet medical need.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alpha-1 Protease Inhibitor Deficiency Report Insights
• Patient Population
• Therapeutic Approaches
• Alpha-1 Protease Inhibitor Deficiency Pipeline Analysis
• Alpha-1 Protease Inhibitor Deficiency Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Alpha-1 Protease Inhibitor Deficiency Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Alpha-1 Protease Inhibitor Deficiency Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Alpha-1 Protease Inhibitor Deficiency Report Assessment
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers

Key Questions
Market Insights:
• What was the Alpha-1 Protease Inhibitor Deficiency market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Alpha-1 Protease Inhibitor Deficiency total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Alpha-1 Protease Inhibitor Deficiency market size during the forecast period (2017–2030)?
• At what CAGR, the Alpha-1 Protease Inhibitor Deficiency market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Alpha-1 Protease Inhibitor Deficiency market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Alpha-1 Protease Inhibitor Deficiency market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What is the disease risk, burden and unmet needs of Alpha-1 Protease Inhibitor Deficiency?
• What is the historical Alpha-1 Protease Inhibitor Deficiency patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Alpha-1 Protease Inhibitor Deficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alpha-1 Protease Inhibitor Deficiency?
• Out of all 7MM countries, which country would have the highest prevalent population of Alpha-1 Protease Inhibitor Deficiency during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the Alpha-1 Protease Inhibitor Deficiency treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Alpha-1 Protease Inhibitor Deficiency in the USA, Europe, and Japan?
• What are the Alpha-1 Protease Inhibitor Deficiency marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Alpha-1 Protease Inhibitor Deficiency?
• How many therapies are developed by each company for Alpha-1 Protease Inhibitor Deficiency treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Alpha-1 Protease Inhibitor Deficiency treatment?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-1 Protease Inhibitor Deficiency therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha-1 Protease Inhibitor Deficiency and their status?
• What are the key designations that have been granted for the emerging therapies for Alpha-1 Protease Inhibitor Deficiency?
• What are the global historical and forecasted market of Alpha-1 Protease Inhibitor Deficiency?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Alpha-1 Protease Inhibitor Deficiency market
• To understand the future market competition in the Alpha-1 Protease Inhibitor Deficiency market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Alpha-1 Protease Inhibitor Deficiency in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Alpha-1 Protease Inhibitor Deficiency market
• To understand the future market competition in the Alpha-1 Protease Inhibitor Deficiency market

Which geography accounted for the largest Alpha-1 Protease Inhibitor Deficiency market size?

The United States accounted for the largest Alpha-1 Protease Inhibitor Deficiency market size.

What is forecasted Alpha-1 Protease Inhibitor Deficiency market size in 2030?

DelveInsight estimates an increase in Alpha-1 Protease Inhibitor Deficiency Market Size during the study period, 2017–2030

What are the present Alpha-1 Protease Inhibitor Deficiency market drivers?

Increasing Prevalence, Biomarkers related studies and Molecular-level Diagnosis aims at driving the market growth.

What are the Alpha-1 Protease Inhibitor Deficiency market barriers?

Lack of awareness and data, Emerging Trials and Economic Burden of the disease.

How many companies are developing drugs for Alpha-1 Protease Inhibitor Deficiency?

Currently, only four key pharma players are developing the drug for Alpha-1 Protease Inhibitor Deficiency.

Which are the leading companies in Alpha-1 Protease Inhibitor Deficiency market?

Key Players – Ovid Therapeutics, GeneTx Biotherapeutics and others.

How is epidemiology segmented for Alpha-1 Protease Inhibitor Deficiency?

Incident and Diagnosed Cases of Alpha-1 Protease Inhibitor Deficiency, Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types and Alpha-1 Protease Inhibitor Deficiency cases by Clinical Manifestations.

Content
1 Key Insights
2 Executive Summary of Alpha-1 Protease Inhibitor Deficiency
3 SWOT Analysis for Alpha-1 Protease Inhibitor Deficiency
4 Alpha-1 Protease Inhibitor Deficiency Market Overview at a Glance
4.1 Market Share (%) Distribution of Alpha-1 Protease Inhibitor Deficiency in 2017
4.2 Market Share (%) Distribution of Alpha-1 Protease Inhibitor Deficiency in 2030
5 Disease Background and Overview
5.1 Introduction
5.2 Cause
5.3 Signs and Symptoms
5.4 Related Disorders and Differential Diagnosis
5.5 Complications
5.6 Genetics of Alpha-1 Protease Inhibitor Deficiency
5.7 Molecular Genetic Pathogenesis
5.8 Diagnosis
5.8.1 Clinical criteria for diagnosis
5.8.2 Disease History and Medical Conditions
5.9 Diagnostic Algorithm
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Alpha-1 Protease Inhibitor Deficiency
7 Country Wise-Epidemiology of Alpha-1 Protease Inhibitor Deficiency
7.1 The United States
7.1.1 Assumptions and Rationale
7.1.2 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United States
7.1.3 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United States
7.1.4 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in the United States
7.1.5 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in the United States
7.2 EU5
7.2.1 Assumptions and Rationale
7.3 Germany
7.3.1 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Germany
7.3.2 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Germany
7.3.3 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Germany
7.3.4 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Germany
7.4 France
7.4.1 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in France
7.4.2 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in France
7.4.3 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in France
7.4.4 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in France
7.5 Italy
7.5.1 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Italy
7.5.2 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Italy
7.5.3 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Italy
7.5.4 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Italy
7.6 Spain
7.6.1 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Spain
7.6.2 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Spain
7.6.3 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Spain
7.6.4 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Spain
7.7 The United Kingdom
7.7.1 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United Kingdom
7.7.2 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United Kingdom
7.7.3 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in the UK
7.7.4 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in the UK
7.8 Japan
7.8.1 Assumptions and Rationale
7.8.2 Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Japan
7.8.3 Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Japan
7.8.4 Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Japan
7.8.5 Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Japan
8 Treatment and Management of Alpha-1 Protease Inhibitor Deficiency
8.1 Recommendations for the management of Alpha-1 Protease Inhibitor Deficiency
8.2 Future treatment options for Alpha-1 Protease Inhibitor Deficiency
8.2.1 Gene Therapy
8.2.2 Topoisomerase Inhibitors
8.2.3 Minocycline
8.2.4 Cannabidiol (CBD)
8.2.5 Protein Phosphatase 2A (PP2A) Inhibitor
9 Unmet Needs
10 Organizations contributing toward Alpha-1 Protease Inhibitor Deficiency
11 KOL’s Views: Alpha-1 Protease Inhibitor Deficiency
12 Patient Journey
12.1 Journey toward a Diagnosis: Diagnosing a Rare form of Alpha-1 Protease Inhibitor Deficiency
13 Case Reports
13.1 A Case of Fundus Oculi Albinoticus Diagnosed as Alpha-1 Protease Inhibitor Deficiency by Genetic Testing – A Japanese Case Study
13.2 Two Angelman families with unusually advanced neurodevelopment carry a start codon variant in the most highly expressed UBE3A isoform: a case report of US
13.3 Alpha-1 Protease Inhibitor Deficiency: A Case Series Assessing Neurological Issues in Adulthood – A European Case Report
14 Emerging Therapies
14.1 Gaboxadol: Ovid Therapeutics
14.1.1 Product Description
14.1.2 Other Development Activities
14.1.3 Clinical Development
14.1.4 Safety and Efficacy
14.2 GeneTx Biotherapeutics
14.2.1 GTX-102
15 Future Gene Therapies
15.1 GeneTx Biotherapeutics
15.1.1 GTX-101
15.2 PTC Therapeutics: GT-AS/AGIL-AS:
15.2.1 Product Description
15.2.2 Other Development Activities
15.3 Sarepta Therapeutics and StrideBio
15.3.1 Development Activities
16 Alpha-1 Protease Inhibitor Deficiency: Seven Major Market Analysis
16.1 Key Findings
16.2 Market Size of Alpha-1 Protease Inhibitor Deficiency in 7MM
17 Market Outlook by Country
17.1 The United States: Market Outlook
17.1.1 United States Market Size
17.2 EU-5 Countries: Market Outlook
17.2.1 Germany
17.2.2 France
17.2.3 Italy
17.2.4 Spain
17.2.5 United Kingdom
17.3 Japan: Market Outlook
17.3.1 Total Market Size of Alpha-1 Protease Inhibitor Deficiency
17.3.2 Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies
18 Market Drivers
19 Market Barriers
20 Market Access and Reimbursement
21 Appendix
21.1 Report Methodology
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight
Table 1: Summary of Alpha-1 Protease Inhibitor Deficiency Market, Epidemiology, and Key Events (2017–2030)
Table 2: Genetic mechanisms giving rise to Alpha-1 Protease Inhibitor Deficiency
Table 3: Molecular genetic testing used in AS after DNA methylation analysis
Table 4: Prevalent Patient Population of Alpha-1 Protease Inhibitor Deficiency in 7MM (2017–2030)
Table 5: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United States (2017–2030)
Table 6: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United States (2017–2030)
Table 7: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in the United States (2017–2030)
Table 8: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in the United States (2017–2030)
Table 9: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Germany (2017–2030)
Table 10: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Germany (2017–2030)
Table 11: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Germany (2017–2030)
Table 12: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Germany (2017–2030)
Table 13: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in France (2017–2030)
Table 14: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in France (2017–2030)
Table 15: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in France (2017–2030)
Table 16: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in France (2017–2030)
Table 17: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Italy (2017–2030)
Table 18: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Italy (2017–2030)
Table 19: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Italy (2017–2030)
Table 20: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Italy (2017–2030)
Table 21: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Spain (2017–2030)
Table 22: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Spain (2017–2030)
Table 23: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Spain (2017–2030)
Table 24: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Spain (2017–2030)
Table 25: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United Kingdom (2017–2030)
Table 26: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in the United Kingdom (2017–2030)
Table 27: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in the UK (2017–2030)
Table 28: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in the UK (2017–2030)
Table 29: Total Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Japan (2017–2030)
Table 30: Diagnosed Prevalent Cases of Alpha-1 Protease Inhibitor Deficiency in Japan (2017–2030)
Table 31: Alpha-1 Protease Inhibitor Deficiency cases by Mutation Types in Japan (2017–2030)
Table 32: Alpha-1 Protease Inhibitor Deficiency associated with Clinical Manifestations in Japan (2017–2030)
Table 33: Feeding & Diet Recommendations
Table 34: Development Recommendations
Table 35: Seizure Types—the following are typical of AS:
Table 36: Treatment for Seizures and CNS
Table 37: Recommendations for the management of Alpha-1 Protease Inhibitor Deficiency
Table 38: Recommendations for the management of Vision & Hearing
Table 39: Recommendations for the management of Behavior
Table 40: Recommendations for the management of Speech and Communication
Table 41: Recommendations for the management of Dental Issues and Drooling
Table 42: General health and Anesthesia Recommendations
Table 43: Scoliosis and Skeletal Recommendations
Table 44: Puberty and Sexual Health Recommendations
Table 45: Organizations contributing to Alpha-1 Protease Inhibitor Deficiency
Table 46: Gaboxadol, Clinical Trial Description, 2020
Table 47: GTX-102, Clinical Trial Description, 2020
Table 48: Seven Major Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 49: United States Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 50: The US Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 51: Germany Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 52: Germany Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 53: France Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 54: France Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 55: Italy Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 56: Italy Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 57: Spain Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 58: Spain Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 59: United Kingdom Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 60: The UK Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)
Table 61: Japan Market Size of Alpha-1 Protease Inhibitor Deficiency in USD Million (2017–2030)
Table 62: Japan Market Size of Alpha-1 Protease Inhibitor Deficiency by Therapies in USD Million (2017–2030)